Skip to main content

Table 3 Medications associated with drug-induced Sweet's syndrome [a-c]

From: Sweet's syndrome – a comprehensive review of an acute febrile neutrophilic dermatosis


Minocycline [110-112]


Nitrofurantoin [113]


Norfloxacin [114]


Ofloxacin [115]


Quinupristin/dalfopristin [118]


Trimethoprim-sulfamethoxazole [11,13]


Carbemazepine [17]


Diazepam [86]

Antihuman immunodeficiency virus drugs

Abacavir (synthetic carbocyclic nucleoside analogue) [69]


Hydralazine [107]


Bortezomib [d] [78-79]


Imatinib mesylate [e] [108,109,401]


Lenalidomide [f] [426]


Clozapine [82]

Antithyroid hormone synthesis drugs

Propylthiouracil [117]

Colony stimulating factors

Granulocyte-colony stimulating factor [39,41,89-105,398]


Granulocyte-macrophage-colony stimulating factor [105,106]


Pegfilgrastim [g] [116]

Contraceptives [83]

Levonorgestrel/ethinyl estradiol (Triphasil) [84]


Levonorgestrel-releasing intrauterine system (Mirena) [85]


Furosemide [88]

Nonsteroidal anti-inflammatory agents

Celecoxib [80]


Diclofenac [87]


All-trans retinoic acid [70-77,417]


13-cis-retinoic acid [81,404]

  1. [a] The possibility of acyclovir-induced Sweet's syndrome cannot be completely ruled out in a 13-year-old girl with systemic lupus erythematosus (that had been diagnosed 3 months earlier and was being treated with oral prednisolone and azathioprine) whose Sweet's syndrome lesions appeared 5 days after beginning intravenous acyclovir treatment for a herpes zoster infection [119].
  2. [b] Photodistributed neutrophilic dermatosis with overlapping features of Sweet's syndrome, acute generalized exanthematous pustulosis and sterile neutrophilic folliculitis with perifollicular vasculopathy developed in a patient who had received antidepressant (amoxapine and citalopram) and anxiolytic (perphenazine) therapy [120].
  3. [c] Additional reports have attributed Sweet's syndrome to medications (minocycline [121], furosemide [122], and hydralazine [123,124]); however, they did not fulfill the criteria proposed by Walker and Cohen [13] for drug-induced Sweet's syndrome.
  4. [d] This drug is a reversible inhibitor of the chymotrypsin-like activity of the 26S proteasome in mammalian cells. It is indicated for the treatment of multiple myeloma patients.
  5. [e] This drug is a protein-tyrosine kinase inhibitor that inhibits the bcr-abl tyrosine kinase, the constitutive abnormal tyrosine kinase created by the Philadelphia chromosome abnormality in chronic myeloid leukemia.
  6. [f] This drug is an amino-substituted analogue of thalidomide. It is an immunomodulatory agent with anti-angiogenic and antineoplastic properties. It is indicated for the treatment of: (1) multiple myeloma and (2) transfusion dependent anemia due to low-risk or intermediate-risk myelodysplastic syndromes.
  7. [g] This drug is a covalent conjugate of recombinant methionyl human granulocyte-colony stimulating factor (Filgrastim) and monomethoxypolyethylene.